Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
China · Delayed Price · Currency is CNY 14.03
+1.28 (10.04%)
Aug 21, 2026, 11:29 AM CST
SHA:603079 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,390 | 3,316 | 2,281 | 2,486 | 2,148 | 2,962 | |
Market Cap Growth | -31.28% | 45.41% | -8.28% | 15.73% | -27.46% | -19.91% |
Enterprise Value | 2,143 | 3,068 | 2,298 | 2,343 | 1,896 | 2,598 |
Last Close Price | 12.75 | 17.56 | 13.35 | 14.36 | 12.31 | 16.77 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.49 | 53.36 | 77.51 | - | 68.24 | 39.09 |
Forward PE | - | 55.60 | 55.60 | 55.60 | 55.60 | 55.60 |
PS Ratio | 2.88 | 3.93 | 2.76 | 3.42 | 2.91 | 3.75 |
PB Ratio | 1.47 | 2.05 | 1.78 | 1.96 | 1.60 | 2.22 |
P/TBV Ratio | 1.75 | 2.46 | 2.23 | 2.46 | 1.96 | 2.57 |
P/OCF Ratio | 15.24 | 23.88 | 15.42 | 38.60 | 52.76 | 39.77 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.58 | 3.63 | 2.78 | 3.22 | 2.57 | 3.29 |
EV/EBITDA Ratio | 15.98 | 21.53 | 21.75 | 133.26 | 32.90 | 19.77 |
EV/EBIT Ratio | 37.34 | 45.75 | 72.85 | - | - | 42.95 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.21 | 0.20 | 0.21 | 0.19 | 0.03 | 0.13 |
Debt / EBITDA Ratio | 2.50 | 2.26 | 2.47 | 13.19 | 0.73 | 1.28 |
Net Debt / Equity Ratio | -0.17 | -0.20 | -0.06 | -0.07 | -0.21 | -0.27 |
Net Debt / EBITDA Ratio | -2.10 | -2.28 | -0.78 | -4.98 | -5.00 | -2.78 |
Net Debt / FCF Ratio | -19.95 | 47.87 | 3.75 | 0.48 | 12.78 | 14.35 |
Asset Turnover | 0.42 | 0.42 | 0.47 | 0.43 | 0.43 | 0.46 |
Inventory Turnover | 2.95 | 3.28 | 3.12 | 2.51 | 2.44 | 2.94 |
Quick Ratio | 3.59 | 3.28 | 1.94 | 1.51 | 1.58 | 1.62 |
Current Ratio | 4.69 | 4.10 | 2.82 | 2.35 | 2.64 | 2.23 |
Return on Equity (ROE) | 4.16% | 4.78% | 2.92% | -4.15% | 2.27% | 5.40% |
Return on Assets (ROA) | 1.79% | 2.10% | 1.13% | -2.02% | -0.37% | 2.18% |
Return on Invested Capital (ROIC) | 3.74% | 4.66% | 2.01% | -4.87% | -0.83% | 5.88% |
Return on Capital Employed (ROCE) | 2.90% | 3.40% | 2.10% | -3.80% | -0.70% | 4.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.24% | 1.87% | 1.29% | -2.17% | 1.47% | 2.56% |
FCF Yield | 0.59% | -0.21% | -0.96% | -7.30% | -1.05% | -0.86% |
Dividend Yield | 0.68% | 0.57% | - | 0.42% | 0.49% | 0.83% |
Payout Ratio | 14.86% | 12.57% | 61.41% | - | 87.12% | 86.42% |
Buyback Yield / Dilution | -9.40% | -2.60% | -2.45% | 3.41% | -1.59% | -2.03% |
Total Shareholder Return | -8.73% | -2.03% | -2.45% | 3.83% | -1.10% | -1.19% |